Novo Nordisk Temettü
Temettü kriter kontrolleri 3/6
Novo Nordisk is a dividend paying company with a current yield of 1.29% that is well covered by earnings.
Anahtar bilgiler
1.3%
Temettü verimi
0.8%
Geri Alım Getirisi
| Toplam Hissedar Getirisi | 2.1% |
| Gelecekteki Temettü Verimi | 2.3% |
| Temettü Büyümesi | -5.9% |
| Bir sonraki temettü ödeme tarihi | n/a |
| Eski temettü tarihi | n/a |
| Hisse başına temettü | US$1.463 |
| Ödeme oranı | 49% |
Son temettü güncellemeleri
Recent updates
Novo Nordisk: A Diabetes Leader Among Big Pharma, But Still Overvalued
Oct 21Multiple Strong Catalysts And Attractive Valuation Make Novo Nordisk A Buy
Sep 18Novo Nordisk: Low Dividend Yield, Decelerated Growth Rates, Hold For Now
Sep 10Novo Nordisk: Great Value Buying Opportunity, Thanks To The Much-Needed Rotation
Aug 18Novo Nordisk: Growth Only Limited By Manufacturing Capacity
Aug 07Novo Nordisk: Better Buying Opportunities Ahead
Jul 26Novo Nordisk: Buy On Dips
Jul 04Novo Nordisk Breaks Out To An All-Time High On China Approval Of Wegovy
Jun 26Novo Nordisk: Leading The Fight Against Diabetes And Obesity
Jun 18Novo Nordisk: Considerable Growth Beyond Ozempic
May 27The FTC Cracks Down On Novo Nordisk's Ozempic
May 03Novo Nordisk: Medicare Coverage To Unlock Another Big Market For Wegovy
Apr 26Novo Nordisk: The Moat Won't Last Forever
Apr 09Shaping The Future Of Obesity Treatment: GLP-1 Agonists At The Forefront
Mar 18Novo Nordisk: My 'Hold' Thesis For 2024 - The Premium Must Be Justified
Mar 07Novo Nordisk, A Very Healthy Pharma Stalwart
Feb 28Novo Nordisk: SOTP After Impressive FY23 And Weight Loss Going Mainstream, Maintain Buy
Feb 23Novo Nordisk: Irrational Exuberance Isn't Worth The Risk
Feb 16Novo Nordisk: Outlook For Weight Loss Drugs In 2024
Jan 22Taking Novo Nordisk To The Next Level
Jan 15Profiting From Obesity Drugs HRTS, Novo Nordisk And Eli Lilly
Jan 02Novo Nordisk: Latest Insights Confirm Exceptionally Bullish Opportunity
Dec 12Novo Nordisk: Eli Lilly's Zepbound Approval Is Not A Threat To Valuation
Nov 24Novo Nordisk: Growing To Potentially Become The First Trillion-Dollar European Champion
Oct 24Novo Nordisk: Catching The Falling Knife Now Could Really Hurt
Sep 22Novo Nordisk: Strong Fundamentals Meet Technical Uptrends
Aug 30Novo Nordisk: Denmark's Coca-Cola
Jul 25The Case For Novo Nordisk: Growth, Dividends, And A New Treatment Frontier
Jul 11Novo Nordisk Is A Hold Despite Explosive Growth In Diabetes And Obesity Care
Jun 23Ödemelerde İstikrar ve Büyüme
Temettü verilerini getirme
İstikrarlı Temettü: NVO's dividend payments have been volatile in the past 10 years.
Büyüyen Temettü: NVO's dividend payments have increased over the past 10 years.
Piyasaya Karşı Temettü Getirisi
| Novo Nordisk Piyasaya Karşı Temettü Getirisi |
|---|
| Segment | Temettü Verimi |
|---|---|
| Şirket (NVO) | 1.3% |
| Pazarın Alt %25'i (US) | 1.5% |
| Pazarın En İyi %25'i (US) | 4.5% |
| Sektör Ortalaması (Pharmaceuticals) | 2.3% |
| Analist tahmini (NVO) (3 yıla kadar) | 2.3% |
Önemli Temettü: NVO's dividend (1.29%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.46%).
Yüksek Temettü: NVO's dividend (1.29%) is low compared to the top 25% of dividend payers in the US market (4.55%).
Hissedarlara Ödenen Kazanç
Kazanç Kapsamı: With its reasonably low payout ratio (49.2%), NVO's dividend payments are well covered by earnings.
Hissedarlara Nakit Ödeme
Nakit Akışı Kapsamı: With its reasonable cash payout ratio (66.4%), NVO's dividend payments are covered by cash flows.